

Simon Lovestone

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7407281/simon-lovestone-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

178
papers

12,399
citations

50
h-index

109
g-index

247
ext. papers

15,959
ext. citations

7.6
avg, IF

5.53
L-index

#	Paper	IF	Citations
178	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022 , 14, 840651	5.3	0
177	Serum from Older Adults Increases Apoptosis and Molecular Aging Markers in Human Hippocampal Progenitor Cells 2021 , 12, 2151-2172		0
176	A missense variant in SHARPIN mediates Alzheimer's disease-specific brain damages. <i>Translational Psychiatry</i> , 2021 , 11, 590	8.6	2
175	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. <i>Genome Biology</i> , 2021 , 22, 90	18.3	6
174	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1452-1464	1.2	4
173	Comorbidity between Alzheimer's disease and major depression: a behavioural and transcriptomic characterization study in mice. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 73	9	1
172	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1628-1640	1.2	4
171	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021 , 13, 712545	5.3	3
170	ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset. <i>Journal of Alzheimer's Disease</i> , 2021 , 79, 423-431	4.3	5
169	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021 , 13, 20	9	22
168	Urinary metabolic phenotyping for Alzheimer's disease. <i>Scientific Reports</i> , 2020 , 10, 21745	4.9	10
167	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020 , 66, 101714	15.4	26
166	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020 , 74, 213-225	4.3	10
165	APOE ϵ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 65	9	13
164	Tau pathology in early Alzheimer's disease is linked to selective disruptions in neurophysiological network dynamics. <i>Neurobiology of Aging</i> , 2020 , 92, 141-152	5.6	8
163	Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer's disease: the MADE Phase II, three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020 , 7, 1-62	1.7	6
162	Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2020 , 77, 164-174	17.2	62

161	Dysregulated Fc gamma receptor-mediated phagocytosis pathway in Alzheimer's disease: network-based gene expression analysis. <i>Neurobiology of Aging</i> , 2020 , 88, 24-32	5.6	6
160	Association of blood-based transcriptional risk scores with biomarkers for Alzheimer disease. <i>Neurology: Genetics</i> , 2020 , 6, e517	3.8	3
159	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020 , 10, 403	8.6	10
158	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020 , 95, 26-45	5.6	17
157	Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1213-1223	1.2	8
156	Differences in cohort study data affect external validation of artificial intelligence models for predictive diagnostics of dementia - lessons for translation into clinical practice. <i>EPMA Journal</i> , 2020 , 11, 367-376	8.8	14
155	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020 , 77, 1353-1368	4.3	4
154	Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. <i>Alzheimer's Research and Therapy</i> , 2020 , 12, 38	9	5
153	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 5	7.3	79
152	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1478-1488	1.2	22
151	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , 2019 , 18, 1034-1044	24.1	45
150	Common brain disorders are associated with heritable patterns of apparent aging of the brain. <i>Nature Neuroscience</i> , 2019 , 22, 1617-1623	25.5	157
149	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019 , 15, 817-827	1.2	26
148	Genetic and Real-World Clinical Data, Combined with Empirical Validation, Nominate Jak-Stat Signaling as a Target for Alzheimer's Disease Therapeutic Development. <i>Cells</i> , 2019 , 8,	7.9	15
147	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019 , 15, 776-787	1.2	74
146	Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. <i>BMJ Open</i> , 2019 , 9, e024498	3	5
145	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019 , 11, 26	9	43
144	Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. <i>Frontiers in Neuroscience</i> , 2019 , 13, 164	5.1	106

143	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019 , 5, eaau7220	14.3	44
142	Tackling gaps in developing life-changing treatments for dementia. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 241-253	6	11
141	Recruitment, Retainment, and Biomarkers of Response; A Pilot Trial of Lithium in Humans With Mild Cognitive Impairment. <i>Frontiers in Molecular Neuroscience</i> , 2019 , 12, 163	6.1	6
140	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
139	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019 , 5, 933-938	6	29
138	Genetic architecture of subcortical brain structures in 38,851 individuals. <i>Nature Genetics</i> , 2019 , 51, 1624-1636	36.8	81
137	Heterogeneous patterns of brain atrophy in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 65, 98-108	5.6	52
136	Gait in Mild Alzheimer's Disease: Feasibility of Multi-Center Measurement in the Clinic and Home with Body-Worn Sensors: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 63, 331-341	4.3	29
135	Imaging A β and tau in early stage Alzheimer's disease with [F]AV45 and [F]AV1451. <i>EJNMMI Research</i> , 2018 , 8, 19	3.6	10
134	Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1580-1588	1.2	73
133	Amyloid β -synaptotoxicity is Wnt-PCP dependent and blocked by fasudil. <i>Alzheimer's and Dementia</i> , 2018 , 14, 306-317	1.2	46
132	Alzheimer's disease in humans and other animals: A consequence of postreproductive life span and longevity rather than aging. <i>Alzheimer's and Dementia</i> , 2018 , 14, 195-204	1.2	44
131	No association of salivary total tau concentration with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018 , 70, 125-127	5.6	35
130	Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer's disease. <i>Genome Medicine</i> , 2018 , 10, 51	14.4	27
129	Cross-sectional and longitudinal analyses of outdoor air pollution exposure and cognitive function in UK Biobank. <i>Scientific Reports</i> , 2018 , 8, 12089	4.9	30
128	Clusterin Is Required for β -Amyloid Toxicity in Human iPSC-Derived Neurons. <i>Frontiers in Neuroscience</i> , 2018 , 12, 504	5.1	25
127	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. <i>Brain</i> , 2018 , 141, 2721-2739	11.2	19
126	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. <i>Scientific Reports</i> , 2018 , 8, 11592	4.9	18

125	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 439	5.3	7
124	A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1181-1198	4.3	62
123	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 409	5.3	20
122	A β 2/A β 0 and A β 2/A β 8 Ratios Are Associated with Measures of Gait Variability and Activities of Daily Living in Mild Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2018 , 65, 1377-1383	4.3	13
121	Mitochondrial genes are altered in blood early in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 53, 36-47	5.6	78
120	Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach. <i>Computational and Structural Biotechnology Journal</i> , 2017 , 15, 1-7	6.8	9
119	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. <i>Hippocampus</i> , 2017 , 27, 653-667	3.5	18
118	Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel F-labelled PET tracer targeting P2X7. <i>EJNMMI Research</i> , 2017 , 7, 31	3.6	39
117	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 31	9	27
116	The midlife cognitive profiles of adults at high risk of late-onset Alzheimer's disease: The PREVENT study. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1089-1097	1.2	35
115	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 809-817	4.3	40
114	Targeted neurogenesis pathway-based gene analysis identifies ADORA2A associated with hippocampal volume in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017 , 60, 92-103	5.6	42
113	No Genetic Overlap Between Circulating Iron Levels and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 85-99	4.3	7
112	Effects of freezer storage time on levels of complement biomarkers. <i>BMC Research Notes</i> , 2017 , 10, 5592.3	2.3	9
111	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 85	9	36
110	A Multi-Cohort Study of ApoE e4 and Amyloid- β Effects on the Hippocampus in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017 , 56, 1159-1174	4.3	25
109	NRF2 deficiency replicates transcriptomic changes in Alzheimer's patients and worsens APP and TAU pathology. <i>Redox Biology</i> , 2017 , 13, 444-451	11.3	107
108	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017 , 49, 1373-1384	36.3	508

107	Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017 , 3, 612-621	6	33
106	[P4030]: AMYLOID SYNAPTOTOXICITY DRIVES AMYLOID PRODUCTION 2017 , 13, P1306-P1306		
105	Association of blood lipids with Alzheimer's disease: A comprehensive lipidomics analysis. <i>Alzheimer's and Dementia</i> , 2017 , 13, 140-151	1.2	90
104	[P1027]: PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY 2017 , 13, P243		
103	[P3051]: COULD COMPLEMENT INHIBITION BE A GOOD THERAPEUTIC TARGET IN ALZHEIMER'S DISEASE? 2017 , 13, P950		
102	[P4033]: DEEP AND FREQUENT PHENOTYPING: A FEASIBILITY STUDY FOR EXPERIMENTAL MEDICINE IN DEMENTIA 2017 , 13, P1268-P1269		2
101	[P4026]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIF-AD FEDERATION STUDY 2017 , 13, P1356-P1357		
100	[P1048]: PET TAU AND AMYLOID-BETA DIFFER IN THEIR RELATIONSHIP TO AGE, COGNITION AND CSF BIOMARKERS IN MILD ALZHEIMER'S DISEASE: AN OBSERVATIONAL STUDY 2017 , 13, P456-P457		
99	[P2012]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIF-AD): THE BIOMARKER DISCOVERY STUDY 2017 , 13, P691-P692		1
98	[P2023]: MARKERS OF CIRCADIAN CLOCK FUNCTION IN ALZHEIMER'S DISEASE 2017 , 13, P696-P696		
97	[F10202]: DISCOVERY AND VALIDATION OF MULTIMODAL BIOMARKER SIGNATURES RELATING TO ALZHEIMER'S DISEASE PATHOLOGY AND PROGRESSION 2017 , 13, P174-P175		
96	PET Tau and Amyloid Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2017 , 60, 283-293	4.3	44
95	Are premorbid abnormal personality traits associated with behavioural and psychological symptoms in dementia?. <i>International Journal of Geriatric Psychiatry</i> , 2016 , 31, 1050-5	3.9	18
94	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. <i>European Radiology</i> , 2016 , 26, 2597-610	8	29
93	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. <i>Neurobiology of Aging</i> , 2016 , 40, 68-77	5.6	78
92	Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project. <i>Lancet Psychiatry</i> , 2016 , 3, 179-86	23.3	139
91	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 1105-14	4.3	24
90	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2016 , 49, 659-69	4.3	26

89	Blood-Based Biomarker Candidates of Cerebral Amyloid Using PiB PET in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , 2016 , 52, 561-72	4.3	31
88	Predictors of care home and hospital admissions and their costs for older people with Alzheimer's disease: findings from a large London case register. <i>BMJ Open</i> , 2016 , 6, e013591	3	38
87	Complement Biomarkers as Predictors of Disease Progression in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016 , 54, 707-16	4.3	33
86	Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. <i>BMJ Open</i> , 2016 , 6, e012177	3	31
85	Better together for better dementia research and care. <i>Lancet Psychiatry</i> , 2016 , 3, 503-4	23.3	
84	Comparing biological markers of Alzheimer's disease across blood fraction and platforms: Comparing apples to oranges. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016 , 3, 27-34	5.2	35
83	Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 645-53	1.2	58
82	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. <i>Brain Topography</i> , 2016 , 29, 296-307	4.3	27
81	A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2016 , 8, 33	9	11
80	Novel genetic loci underlying human intracranial volume identified through genome-wide association. <i>Nature Neuroscience</i> , 2016 , 19, 1569-1582	25.5	147
79	Development and Application of Ultra-Performance Liquid Chromatography-TOF MS for Precision Large Scale Urinary Metabolic Phenotyping. <i>Analytical Chemistry</i> , 2016 , 88, 9004-13	7.8	71
78	Common genetic variants influence human subcortical brain structures. <i>Nature</i> , 2015 , 520, 224-9	50.4	601
77	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. <i>Brain</i> , 2015 , 138, 1327-38	11.2	211
76	Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions. <i>Lancet Neurology</i> , 2015 , 14, 926-944	24.1	187
75	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. <i>Brain Topography</i> , 2015 , 28, 746-759	4.3	54
74	Blood protein predictors of brain amyloid for enrichment in clinical trials?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015 , 1, 48-60	5.2	37
73	Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease. <i>Journal of Proteome Research</i> , 2015 , 14, 5063-76	5.6	26
72	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 658-71	1.2	146

71	The Notch intracellular domain represses CRE-dependent transcription. <i>Cellular Signalling</i> , 2015 , 27, 621-9	4.9	23
70	Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 44, 79-92	4.3	26
69	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 741-50	4.3	2
68	Tract Based Spatial Statistic Reveals No Differences in White Matter Microstructural Organization between Carriers and Non-Carriers of the APOE e4 and e2 Alleles in Young Healthy Adolescents. <i>Journal of Alzheimer's Disease</i> , 2015 , 47, 977-84	4.3	11
67	Blood Protein Markers of Neocortical Amyloid- β Burden: A Candidate Study Using SOMAscan Technology. <i>Journal of Alzheimer's Disease</i> , 2015 , 46, 947-61	4.3	40
66	Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology. <i>Frontiers in Neurology</i> , 2015 , 6, 236	4.1	77
65	Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015 , 5, 581-94	5.3	22
64	Circulating Proteomic Signatures of Chronological Age. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015 , 70, 809-16	6.4	81
63	Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1121-2	1.2	14
62	Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. <i>Alzheimer's and Dementia</i> , 2015 , 11, 549-60	1.2	159
61	A phase II trial of tideglusib in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 75-88	4.3	276
60	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. <i>Journal of Alzheimer's Disease</i> , 2015 , 45, 851-64	4.3	9
59	A Subset of Cerebrospinal Fluid Proteins from a Multi-Analyte Panel Associated with Brain Atrophy, Disease Classification and Prediction in Alzheimer's Disease. <i>PLoS ONE</i> , 2015 , 10, e0134368	3.7	21
58	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014 , 35, 2883.e3-2883.e10	5.6	8
57	Blood biomarkers for Alzheimer's disease. <i>Genome Medicine</i> , 2014 , 6, 65	14.4	3
56	Methylomic profiling implicates cortical deregulation of ANK1 in Alzheimer's disease. <i>Nature Neuroscience</i> , 2014 , 17, 1164-70	25.5	356
55	Plasma proteins predict conversion to dementia from prodromal disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 799-807.e2	1.2	139
54	No differences in hippocampal volume between carriers and non-carriers of the ApoE ϵ 4 and ϵ 2 alleles in young healthy adolescents. <i>Journal of Alzheimer's Disease</i> , 2014 , 40, 37-43	4.3	35

53	Developing novel blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 109-14	1.2	111
52	Cross-region reduction in 5-hydroxymethylcytosine in Alzheimer's disease brain. <i>Neurobiology of Aging</i> , 2014 , 35, 1850-4	5.6	96
51	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. <i>Alzheimer's and Dementia</i> , 2014 , 10, 724-34	1.2	133
50	CERAD neuropsychological compound scores are accurate in detecting prodromal Alzheimer's disease: a prospective AddNeuroMed study. <i>Journal of Alzheimer's Disease</i> , 2014 , 39, 679-90	4.3	30
49	P3-113: NOVEL CANDIDATE BLOOD PROTEOME MARKERS OF ALZHEIMER'S DISEASE BRAIN AMYLOID BURDEN: A MULTIPLEX TMT-LC/MS-MS DISCOVERY APPROACH 2014 , 10, P669-P670		
48	O3-04-03: CROSS-TISSUE METHYLOMIC PROFILING IN ALZHEIMER'S DISEASE 2014 , 10, P215-P215		
47	Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort. <i>Frontiers in Aging Neuroscience</i> , 2014 , 6, 145	5.3	23
46	Advanced glycation end products, dementia, and diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014 , 111, 4743-4	11.5	28
45	Clusterin regulates Amyloid toxicity via Dickkopf-1-driven induction of the wnt-PCP-JNK pathway. <i>Molecular Psychiatry</i> , 2014 , 19, 88-98	15.1	153
44	Genetic predisposition to increased blood cholesterol and triglyceride lipid levels and risk of Alzheimer disease: a Mendelian randomization analysis. <i>PLoS Medicine</i> , 2014 , 11, e1001713	11.6	62
43	Developing a new model for patient recruitment in mental health services: a cohort study using Electronic Health Records. <i>BMJ Open</i> , 2014 , 4, e005654	3	27
42	Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS). <i>Journal of Neurodevelopmental Disorders</i> , 2014 , 6, 42	4.6	8
41	The future of blood-based biomarkers for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, 115-312		196
40	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. <i>PLoS ONE</i> , 2014 , 9, e94661	3.7	90
39	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013 , 45, 1452-8	36.3	2714
38	Trait, state, and mechanism: looking back, looking forward, and understanding why. <i>Journal of Alzheimer's Disease</i> , 2013 , 33 Suppl 1, S23-33	4.3	1
37	Identification of cis-regulatory variation influencing protein abundance levels in human plasma. <i>Human Molecular Genetics</i> , 2012 , 21, 3719-26	5.6	71
36	Down syndrome with and without dementia: an in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease. <i>NeuroImage</i> , 2011 , 57, 63-68	7.9	24

35	The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 75-82	3.9	106
34	O2-05-01: Clusterin, an amyloid chaperone protein in plasma is associated with longitudinal brain atrophy in mild cognitive impairment 2010 , 6, S106-S107		
33	MRI measures of Alzheimer's disease and the AddNeuroMed study. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1180, 47-55	6.5	104
32	AddNeuroMed--the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1180, 36-46	6.5	140
31	Biomarkers in brain disease. Preface. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1180, vii	6.5	1
30	Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US\$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. <i>International Psychogeriatrics</i> , 2007 , 19, 337	3.4	
29	Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. <i>Expert Review of Proteomics</i> , 2007 , 4, 227-38	4.2	40
28	Neurogenetics: Scientific and Clinical Advances (Series: Neurological Disease and Therapy, Volume 75) Editor: DAVID R. LYNCH New York: Taylor & Francis, 2006, US\$198.95 Hardback, 755 pp. ISBN 0 8247 2942 0. <i>International Psychogeriatrics</i> , 2006 , 1	3.4	
27	Genetics, molecular biology, neuropathology and phenotype of frontal lobe dementia: a case history. <i>British Journal of Psychiatry</i> , 2002 , 180, 455-60	5.4	2
26	Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. <i>Human Genetics</i> , 2001 , 109, 646-52	6.3	84
25	Acetylcholinesterase treatment--modelling potential demand and auditing practice. <i>International Journal of Geriatric Psychiatry</i> , 2001 , 16, 1136-42	3.9	5
24	Antidepressants enhance glucocorticoid receptor function in vitro by modulating the membrane steroid transporters. <i>British Journal of Pharmacology</i> , 2001 , 134, 1335-43	8.6	122
23	Effects of FTDP-17 mutations on the in vitro phosphorylation of tau by glycogen synthase kinase 3beta identified by mass spectrometry demonstrate certain mutations exert long-range conformational changes. <i>FEBS Letters</i> , 2001 , 493, 40-4	3.8	31
22	Sites of phosphorylation in tau and factors affecting their regulation. <i>Biochemical Society Symposia</i> , 2001 , 67, 73-80		79
21	Differential effects of apolipoprotein E isoforms on phosphorylation at specific sites on tau by glycogen synthase kinase-3 beta identified by nano-electrospray mass spectrometry. <i>FEBS Letters</i> , 2000 , 485, 99-103	3.8	20
20	Susceptibility locus for Alzheimer's disease on chromosome 10. <i>Science</i> , 2000 , 290, 2304-5	33.3	345
19	Long-term predictors of cognitive outcome in a cohort of older people with hypertension. <i>British Journal of Psychiatry</i> , 2000 , 177, 66-71	5.4	81
18	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. <i>Nature Genetics</i> , 1999 , 21, 71-2	36.3	236

17	Alpha-2 macroglobulin gene and Alzheimer disease. <i>Nature Genetics</i> , 1999 , 22, 17-9; author reply 21-2	36.3	88
16	Disturbance of Notch-1 and Wnt signalling proteins in neuroglial balloon cells and abnormal large neurons in focal cortical dysplasia in human cortex. <i>Acta Neuropathologica</i> , 1999 , 98, 465-72	14.3	55
15	Early diagnosis and the clinical genetics of Alzheimer's disease. <i>Journal of Neurology</i> , 1999 , 246, 69-72	5.5	21
14	UK Alzheimer's disease genetics consortium. <i>International Journal of Geriatric Psychiatry</i> , 1999 , 14, 789-93	3.9	11
13	Muscarinic therapies in Alzheimer's disease; from palliative treatments to disease modification. <i>International Journal of Psychiatry in Clinical Practice</i> , 1997 , 1, 15-20	2.4	1
12	It takes Tau to tangle. <i>International Journal of Geriatric Psychiatry</i> , 1996 , 11, 363-368	3.9	
11	Editorial Review. The genetics of Alzheimer's disease—new opportunities and new challenges. <i>International Journal of Geriatric Psychiatry</i> , 1996 , 11, 491-497	3.9	6
10	Stimulation of MAP kinase by v-raf transformation of fibroblasts fails to induce hyperphosphorylation of transfected tau. <i>FEBS Letters</i> , 1995 , 365, 42-6	3.8	38
9	The role of the father in parental postnatal mental health. <i>The British Journal of Medical Psychology</i> , 1995 , 68 (Pt 2), 157-68		21
8	Apolipoprotein e genotype and late paraphrenia. <i>International Journal of Geriatric Psychiatry</i> , 1995 , 10, 147-150	3.9	21
7	A genetic test for Alzheimer's disease?. <i>Psychiatric Bulletin</i> , 1994 , 18, 645-645		5
6	Neurodegenerative Disorders - Mechanisms and Prospects for Therapy. Edited by D. L. Price, H. Thoenen and A. J. Aguayo Chichester: John Wiley & Sons. 1991. 301 pp. £50.00.. <i>British Journal of Psychiatry</i> , 1993 , 162, 294-294	5.4	
5	Long life or old age? (Working with the elderly). <i>Psychiatric Bulletin</i> , 1992 , 16, 168-168		
4	Possible Future Treatments and Preventative Strategies for Alzheimer's Disease325-326		
3	Biological Research on Dementias287-322		
2	ANMerge: A comprehensive and accessible Alzheimer's disease patient-level dataset		1
1	Headache and type 2 diabetes association: a US national ambulatory case-control study		1